Search results
Results from the WOW.Com Content Network
Hyperkalemia is an elevated level of potassium (K +) in the blood. [1] Normal potassium levels are between 3.5 and 5.0 mmol/L (3.5 and 5.0 mEq/L) with levels above 5.5 mmol/L defined as hyperkalemia. [3] [4] Typically hyperkalemia does not cause symptoms. [1] Occasionally when severe it can cause palpitations, muscle pain, muscle weakness, or ...
Treatment efforts may involve many clinical and diagnostic manoeuvers, such as trying to decrease phosphate, [7] normalize vitamin D (calcidiol levels) or decrease PTH and/or alkaline phosphatase levels. [8] However, there is an important lack of randomized clinical studies and recent guidelines (KDIGO 2017) have been recently released on the ...
The AAP Red Book, or Report of the Committee on Infectious Diseases of the American Academy of Pediatrics, is a hardcover, softcover, and electronic reference to the "manifestations, etiology, epidemiology, diagnosis, and treatment of some 200 childhood infectious diseases". The Red Book first appeared as an eight-page booklet in 1938. The most ...
According to the CDC, nephritis/nephrosis/nephritic syndrome was the 9th leading cause of death in the United States in 2017. [45] It was listed as the cause of death for 50,633 out of the total 2,813,503 deaths reported in 2017.
Potassium binders are medications that bind potassium ions in the gastrointestinal tract, thereby preventing its intestinal absorption. This category formerly consisted solely of polystyrene sulfonate, a polyanionic resin attached to a cation, administered either orally or by retention enema to patients who are at risk of developing hyperkalaemia (abnormal high serum potassium levels).
On their own this group of drugs may raise potassium levels beyond the normal range, termed hyperkalemia, which risks potentially fatal arrhythmias. Triamterene, specifically, is a potential nephrotoxin and up to half of the patients on it can have crystalluria or urinary casts .
Hypoaldosteronism is a clinical condition marked by either an aldosterone deficiency or impaired tissue-level action of the hormone. Angiotensin I to Angiotensin II conversion, adrenal aldosterone synthesis and secretion, abnormal target tissue response to aldosterone , and renal renin production and secretion are all potential causes of the ...
There are three mainstays of treatment of hyperkalemia. These are stabilization of cardiac cells , shift of potassium into the cells, and removal of potassium from the body. [ 3 ] [ 14 ] Stabilization of cardiac muscle cells is done by administering calcium intravenously. [ 3 ]